摘要
目的观察瑞芬太尼靶控输注(TCI)时患者呼吸抑制的50%有效靶控血浆浓度(CP50)。方法择期硬膜外-腰麻联合麻醉患者80例(ASAⅠ-Ⅱ),应用TCI靶控输注系统,按不同血浆靶控浓度随机分为8组(n=10):Ⅰ组(1.0μg·L^-1、Ⅱ组(1.5μg·L^-1、Ⅲ组(2.0μg·L^-1、Ⅳ组(2.5μg·L^-1、Ⅴ组(3.0μg·L^-1、Ⅵ组(3.5μg·L^-1、Ⅶ组(4.0μg·L^-1、Ⅷ组(4.5μg·L^-1。应用半数效量序贯法计算瑞芬太尼TCI时患者呼吸抑制的CP50及其95%可信区间(95%CI)。结果瑞芬太尼TCI时患者呼吸抑制的CP50为2.48μg·L^-1CP50的95%CI为2.24-2.74μg·L^-1结论瑞芬太尼TCI时患者呼吸抑制的CP50为2.
Objective To investigate the half-effective target plasma concentration ( CP50 ) of remifentanil for respiratory depression Methods Eighty patients of ASA status Ⅰ-Ⅱ undergoing combined spinal epidural ( CSE ) anesthesia were randomly divided into eight groups ( n = 10 ) according to the target plasma concentration of remifentanil ( target plasma concentration of 1.0μg·L^-1,1.5 μg·L^-1,2.0 μg·L^-1,2.5μg·L^-1,3.0μg·L^-1,3.5μg·L^-1,4.0 μg·L^-1, 4.5μg·L^-1). Cp50 and 95% confidence interval (95% CI)causing respiratory depression were determined by probit analysis. Results The CP50 of remifentanil causing respiratory depression was 2.48μg·L^-1, and 95% CI was 2.24 - 2.73μg·L^-1. Conclusion The Cp50 of remifentanil causing respiratory depression was 2.48μg·L^-1.
出处
《新乡医学院学报》
CAS
2009年第3期263-265,共3页
Journal of Xinxiang Medical University
基金
南方医科大学新业务新技术课题(编号:2006019)
关键词
瑞芬太尼
靶控输注
呼吸抑制
靶控血浆浓度
remifentanil
target controlled infusion
respiratory depression
target plasma concentration